News > DGCI slaps notice on Glenmark's Fabiflu for false claims, high price

DGCI slaps notice on Glenmark's Fabiflu for false claims, high price

CDSCO has issued a show cause notice to Mumbai-based pharmaceutical giant Glenmark regarding the "false claims and pricing" of their recently-approved generic version of Covid-19 drug favipiravir, Fabiflu.

CDSCO said that it received a complaint that the total cost of treatment with Fabiflu will be around Rs 12,500, and the cost proposed by Glenmark is "not in the interest of the poor, lower middle class and middle-class people of India".